Allied Market Research published a report, titled, “HIV Drug Market by Medication class [multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), fusion inhibitors (FI), entry inhibitors, and HIV integrase stand transfer inhibitors] – Global Opportunity Analysis and Industry Forecast, 2014-2022.” According to the report, the global HIV drug market is anticipated to bring in $26,458 million by 2022, airing a CAGR of 3.7% throughout the forecast period 2016-2022. Read More